15.01.2020
- Eli Lilly has agreed to pay around $1.1 billion cash to buy Dermira, a biopharma focused on developing therapies for chronic skin conditions. The acquisition will add lebrikizumab...
16.08.2017
- US biotech Dermira has agreed to license certain rights from Swiss drugmaker Roche and its subsidiary Genentech for the investigational atopic dermatitis drug, lebrikizumab. The...
